unknown
Stage
2022
Founded
1
Investors
About
Alterome Therapeutics is a clinical-stage biotechnology company developing alteration-specific small-molecule targeted therapies for cancer. It is advancing a pipeline that includes ALTA3263, a Phase 1 candidate enrolling patients with advanced solid tumors bearing KRAS mutations.
Explore Alterome Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.